title: Mucinous ovarian cancer: A therapeutic review.
abstract: Mucinous ovarian cancer represents approximately 3% of epithelial ovarian cancers (EOC). Despite this seemingly low prevalence, it remains a diagnostic and therapeutic conundrum that has resulted in numerous attempts to adopt novel strategies in managing this disease. Anecdotally, there has been a prevailing notion that established gold standard systemic regimens should be substituted for those utilised in cancers such as gastrointestinal (GI) malignancies; tumours that share more biological similarities than other EOC subtypes. This review summarises the plethora of small studies which have adopted this philosophy and influenced the design of the multinational GOG142 study, which was ultimately terminated due to poor accrual. To date, there is a paucity of evidence to support delivering 'GI style' chemotherapy for mucinous ovarian cancer over and above carboplatin-paclitaxel doublet therapy. Hence there is an urge to develop studies focused on targeted therapeutic agents driven by refined mutational analysis and conducted within the context of harmonised international collaborations.
authors.affiliation: Mater Health Services, Raymond Terrace, Brisbane, QLD 4101, Australia.
authors.forename: Wen
authors.initials: W
authors.lastname: Xu
authors.affiliation: School of Medicine, University of Queensland, St Lucia, QLD 4072, Australia.
authors.forename: Jack
authors.initials: J
authors.lastname: Rush
authors.affiliation: UQ/Mater McAuley Library, The University of Queensland Library, Brisbane 4101, Australia.
authors.forename: Kirsty
authors.initials: K
authors.lastname: Rickett
authors.affiliation: Mater Health Services, Raymond Terrace, Brisbane, QLD 4101, Australia; School of Medicine, University of Queensland, St Lucia, QLD 4072, Australia; Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD 4102, Australia. Electronic address: Jermaine.Coward@health.qld.gov.au.
authors.forename: Jermaine I G
authors.initials: JI
authors.lastname: Coward
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy* / Q000453:epidemiology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents
keywords: Chemotherapy; Gastrointestinal cancers; Mucinous ovarian cancer; Targeted therapy